{'fraction_non_alphanumeric': 0.024630541871921183, 'fraction_numerical': 0.003940886699507389, 'mean_word_length': 6.257142857142857, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
No Detectable Alterations in Immunogenicity following Terminal Severe Dry‐Heat Treatment of High‐Purity Factor VIII (Liberate) and Factor IX (HP9) Concentrates

We used monoclonal antibody ELISAs, antigen molecular size distribution, competition ELISA and neonatal mouse immune tolerance methods to detect potential neoantigen formation and increased immunogenicity following severe dry‐heat treatment of high‐purity factor VIII (Liberate) and factor IX concentrates. To provide positive controls, concentrates were heated in solution (70°C for 2 h) to produce denaturation on purpose. The competition ELISA applied to factor IX proved particularly useful for quantifying differences between the positive control and the dry‐heated/unheated concentrates. None of the test systems employed by us indicated any detectable neoantigen formation or any alteration in immunogenicity following terminal severe dry‐heat treatment of the high‐purity concentrates, and this finding is supported by clinical experience so far.